The effects of somatostatin and ursodeoxycholic acid in preventing the ischemic injury of the liver following Pringle maneuver in obstructive jaundice-rat model.
OBJECTIVE
In our study, the effects of somatostatin (SS) and ursodeoxycholic acid (UDCA) on ischemic liver injury were studied in (obstructive) jaundice-rat model.


METHODS
For this purpose, jaundice was produced in the first four groups by binding of their choleducts. We performed just laparotomy to the other four groups of animals. To groups 1 and 5, SS was given 15 mcg/kg/day intraperitoneally, and to groups 2 and 6, UDCA was given 20 mg/kg/day enterally. No drugs were given to any other group. At the end of one week, a procedure with ischemia of the liver for 60 minutes followed by reperfusion for 2 hours, was performed to each rat except for groups 4 and 8. Following this procedure, they were sacrificed. The blood samples were taken to measure SGOT, SGPT, ALP, LDH, total and direct bilirubin levels, while liver biopsies were taken for histopathological evaluation.


RESULTS
Under normothermic conditions, following 60-minute liver ischemia period, no irreversible histopathological changes were detected. However, increases in liver necrosis parameters were noted biochemically. SS and UDCA were thought to be effective in preventing the injury by decreasing the liver enzymes levels to a significant degree. The damage of the hepatic ischemic injury was found to be more meaningful and prominent in liver with jaundice.


CONCLUSIONS
In this study, it was noted that SS and UDCA decrease the effects of cholestatic hepatic injury especially and improve the condition.
Pergel
Ahmet
A
Department of General Surgery, Istanbul University. Cerrahpasa Medical Faculty, Istanbul, Turkey.
Zengin
Kagan
K
Cercel
Ali
A
Aki
Hilal
H
Kaya
Safiye
S
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D002756:Cholagogues and Choleretics / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D006728:Hormones / Q000627:therapeutic use*; D041781:Jaundice, Obstructive / Q000503:physiopathology / Q000601:surgery*; D008099:Liver / Q000473:pathology*; D009336:Necrosis; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000517:prevention & control*; D013004:Somatostatin / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use*; D014656:Vascular Surgical Procedures
D002756:Cholagogues and Choleretics; D006728:Hormones; D014409:Tumor Necrosis Factor-alpha; D013004:Somatostatin; D014580:Ursodeoxycholic Acid; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase